Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A narratively synthesized review proposing a clinical implementation framework for RSV vaccination in cardiovascular disease, grounded in trial evidence for respiratory but not cardiovascular endpoints.
Multiple randomized trials and meta-analyses support reductions in major adverse cardiovascular events, cardiovascular mortality, and all-cause mortality in secondary-prevention populations, with particularly persuasive evidence after myocardial infarction, though the source does not report specific effect sizes or confidence intervals.